Curated News:

Medical Meetings

Add to Favorites Subscribe Share
fbshare-Medical Meetings

Showing results

36113620 of 3636
MontefioreLogo2010.jpg

Article ID: 603861

Statin and Aspirin Use Linked to Improved Survival in Women with Endometrial Cancer

Montefiore Health System

Study Examines Effects of Lipid-Lowering Medicines on Cancer Patients Treated for High Cholesterol, Diabetes and Heart Disease

Released:
3-Jun-2013 5:00 PM EDT
mmc-logo.gif

Article ID: 603848

Are Smartphones Disrupting Your Sleep? Mayo Clinic Study Examines the Question

Mayo Clinic

Smartphones and tablets can make for sleep-disrupting bedfellows. One cause is believed to be the bright light-emitting diodes that allow the use of mobile devices in dimly lit rooms; the light exposure can interfere with melatonin, a hormone that helps control the natural sleep-wake cycle. But there may be a way to check your mobile device in bed and still get a good night’s sleep. A Mayo Clinic study suggests dimming the smartphone or tablet brightness settings and holding the device at least 14 inches from your face while using it will reduce its potential to interfere with melatonin and impede sleep.

Released:
3-Jun-2013 3:40 PM EDT
Yale_RoyHerbst-May2013.jpeg

Article ID: 603807

Yale Cancer Center Carves New Path in Immunotherapy

NCI-Designated Cancer Centers

Cancer immunotherapy is showing promise in treating patients with a variety of advanced, metastatic tumors, as evidenced by two newly unveiled studies from Yale Cancer Center.

Released:
3-Jun-2013 11:00 AM EDT
PennMed_logo.png

Article ID: 603772

Cancer Drug Shortages Hit 83 Percent of U.S. Oncologists

Perelman School of Medicine at the University of Pennsylvania

Eighty-three percent of cancer doctors report that they’ve faced oncology drug shortages, and of those, nearly all say that their patients’ treatment has been impacted, according to a study from researchers at the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 2013 annual meeting of the American Society of Clinical Oncology (Abstract #CRA6510). The results showed that shortages – which have hit especially hard among drugs to treat pediatric, gastrointestinal and blood cancers – have left physicians surveyed unable to prescribe standard chemotherapies for a range of cancers.

Released:
3-Jun-2013 7:30 AM EDT
Ludwig.jpg

Article ID: 603791

A One-Two Punch Against Cancer

Ludwig Cancer Research

A team of researchers led by Jedd Wolchok of the Ludwig Center at MSKCC presented data today at the ASCO Annual Meeting showing promising results from a Phase I clinical trial evaluating the concurrent use of two immunotherapies for the treatment of advanced melanoma.

Released:
2-Jun-2013 12:00 PM EDT
Jefferson4CHP3002.jpg
  • Embargo expired:
    2-Jun-2013 9:30 AM EDT

Article ID: 603689

Therapy That Heats and Destroys Bone Tumors Eases Patients’ Pain

Thomas Jefferson University

Patients with cancer that has spread to their bones are often treated with radiation therapy to reduce pain. But if that treatment doesn’t work, or can’t be used again, a second, effective option now exists. Results of a clinical trial on the new therapy, presented by a researcher at Jefferson’s Kimmel Cancer Center, is being presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

Released:
30-May-2013 2:00 PM EDT
Jefferson4CHP3002.jpg
  • Embargo expired:
    2-Jun-2013 9:00 AM EDT

Article ID: 603686

Abnormalities in HER2 Gene Found in Wide Variety of Advanced Cancers

Thomas Jefferson University

The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes ‘s expression — among them mutations, amplifications, substitutions, and translocations — have been found in 14 different advanced solid tumors.

Released:
30-May-2013 1:55 PM EDT
UMMC-logo.png

Article ID: 603796

Bevacizumab (Avastin) as Adjuvant in Newly Diagnosed Glioblastoma Fails to Improve Survival

University of Maryland Medical Center/School of Medicine

Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients newly diagnosed with glioblastoma, a very aggressive form of brain cancer, researchers have found. The results of the large, multicenter study are being presented today at the American Society of Clinical Oncology (ASCO) annual meeting.

Released:
2-Jun-2013 9:00 AM EDT
mmc-logo.gif
  • Embargo expired:
    2-Jun-2013 7:30 AM EDT

Article ID: 603763

US Oncologists Report High Career Satisfaction, Yet Many Suffer Symptoms of Burnout

Mayo Clinic

Even though a majority of U.S. oncologists report satisfaction with their careers, many say they have experienced at least one symptom of burnout, a Mayo Clinic-led study has found. The study was released during the American Society of Clinical Oncology’s annual meeting in Chicago.

Released:
31-May-2013 12:20 PM EDT
PennMed_logo.png

Article ID: 603771

Targeted Therapy Sorafenib Shows Success in Advanced Differentiated Thyroid Cancer Patients

Perelman School of Medicine at the University of Pennsylvania

The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology’s annual meeting (Abstract #4).

Released:
2-Jun-2013 7:30 AM EDT

Showing results

36113620 of 3636

Chat now!